Benjamin Jackson

Benjamin Jackson is an analyst at Jeffries who has recently gained attention for questioning the decision of Novo Nordisk to appoint Maziar Mike Doustdar as the new CEO. His insights reflect concerns in the financial community regarding the company's strategic choices amidst a challenging market landscape for obesity treatments.